Stockreport

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update [Yahoo! Finance]

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF First patient administered BDC-3042 in a Phase 1/2 dose-escalation and expansion clinical study Cash balance of $141.4 million as of September 30, 2023 anticipated to [Read more]